Y Combinator placing a bet on a new generation of biotech start-ups

Y CombinatorY Combinator, the well-known Silicon Valley accelerator, is betting that biotech start-ups that use the latest computer science technologies such as machine learning will grow much more quickly than their counterparts and, as a result, should be funded more like tech start-ups. Read more about the team’s thinking here.

Tom Ballard

By Tom Ballard, Chief Alliance Officer,
Pershing Yoakley & Associates. P.C.

eNews & Updates

Sign up to receive posts via email.

Connect With Us

Upcoming Events

Links to Partners